Skip to content

Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.

Powered by THEMA

Current Report · Items 5.02, 9.01 · 8-K

Johnson & Johnson

JNJNYSEEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026.…

Filed Aug 4, 2026Accepted Aug 4, 2026, 8:48 AM EDTCIK 200406Accession 0000200406-26-000167

View company →Permanent SEC source ↗

Press release in this filing

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September NEW BRUNSWICK, →

Company context

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Current securities

JNJNYSE · EQUITY · Current

Recent company filings

Registered securities in this filing

Johnson & Johnson · 8-K · Filed 2026-08-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, Par Value $1.00

Symbol: JNJ
Exchange: NYSE
Classification: COMMON
Status: Current

Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

1.150% Notes Due November 2028

Symbol: JNJ28
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

2.700% Notes Due February 2029

Symbol: JNJ29B
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-4

Dimensions: us-gaap:StatementClassOfStockAxis

3.200% Notes Due June 2032

Symbol: JNJ32
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-5

Dimensions: us-gaap:StatementClassOfStockAxis

3.050% Notes Due February 2033

Symbol: JNJ33B
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-6

Dimensions: us-gaap:StatementClassOfStockAxis

1.650% Notes Due May 2035

Symbol: JNJ35
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-7

Dimensions: us-gaap:StatementClassOfStockAxis

3.350% Notes Due June 2036

Symbol: JNJ36A
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-8

Dimensions: us-gaap:StatementClassOfStockAxis

3.350% Notes Due February 2037

Symbol: JNJ37B
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-9

Dimensions: us-gaap:StatementClassOfStockAxis

3.550% Notes Due June 2044

Symbol: JNJ44
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-10

Dimensions: us-gaap:StatementClassOfStockAxis

3.600% Notes Due February 2045

Symbol: JNJ45
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-11

Dimensions: us-gaap:StatementClassOfStockAxis

3.700% Notes Due February 2055

Symbol: JNJ55
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-12

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000020040626000167 · 11 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026. The Company’s related press release is attached to this Report as Exhibit 99.1.